Amundi Takes $374,000 Position in Medifast, Inc. (NYSE:MED)

Amundi purchased a new stake in shares of Medifast, Inc. (NYSE:MED - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 21,215 shares of the specialty retailer's stock, valued at approximately $374,000. Amundi owned about 0.19% of Medifast at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Prescott Group Capital Management L.L.C. bought a new position in shares of Medifast in the fourth quarter valued at about $1,938,000. JPMorgan Chase & Co. raised its holdings in Medifast by 156.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 57,455 shares of the specialty retailer's stock valued at $1,100,000 after acquiring an additional 35,017 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Medifast by 14.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 169,409 shares of the specialty retailer's stock worth $3,242,000 after acquiring an additional 20,832 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Medifast during the third quarter worth approximately $348,000. Finally, Benjamin Edwards Inc. acquired a new position in shares of Medifast in the third quarter valued at approximately $256,000. 95.51% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, DA Davidson dropped their target price on Medifast from $17.00 to $16.50 and set a "neutral" rating for the company in a report on Wednesday, February 19th.

Remove Ads

Medifast Stock Down 1.4 %

Shares of MED traded down $0.21 during trading hours on Monday, hitting $14.14. 214,543 shares of the company were exchanged, compared to its average volume of 327,165. The company has a market cap of $154.61 million, a price-to-earnings ratio of 78.53 and a beta of 1.13. The firm's fifty day moving average is $15.01 and its 200 day moving average is $17.23. Medifast, Inc. has a fifty-two week low of $13.57 and a fifty-two week high of $39.14.

Medifast (NYSE:MED - Get Free Report) last issued its earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.26. Medifast had a return on equity of 10.64% and a net margin of 0.35%. The firm had revenue of $119.00 million during the quarter, compared to the consensus estimate of $114.25 million. Analysts anticipate that Medifast, Inc. will post 0.51 EPS for the current year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.